First Time Loading...

Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 762.7 USD -1.81%
Updated: May 2, 2024
Section:
 

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is 374.85 USD. Compared to the current market price of 762.7 USD, Eli Lilly and Co is Overvalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
Base Case
374.85 USD
Overvaluation 51%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

21.2
P/S
P/S
Price to Sales
21.2
vs History
1
vs Industry
9
Median 3Y
10.5
Median 5Y
8.3
Industry
2.4
Forward
17.3
More Details
138.2
P/E
P/E
Price to Earnings
138.2
vs History
1
vs Industry
2
Median 3Y
51.8
Median 5Y
39.2
Industry
22.9
Forward
60.5
More Details
170.8
P/OCF
P/OCF
Price to OCF
170.8
vs History
1
vs Industry
2
Median 3Y
40.7
Median 5Y
32
Industry
17.1
More Details
140.1
P/FCFE
P/FCFE
Price to FCFE
140.1
vs History
4
vs Industry
5
Median 3Y
52.5
Median 5Y
44.8
Industry
23.2
More Details
67.2
P/B
P/B
Price to Book Value
67.2
vs History
1
vs Industry
1
Median 3Y
34
Median 5Y
34.1
Industry
2.1
More Details
21.8
EV/S
EV/S
Enterprise Value to Sales
21.8
vs History
3
vs Industry
8
Median 3Y
10.9
Median 5Y
8.7
Industry
2.6
Forward
17.7
More Details
27.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
27.5
vs History
1
vs Industry
7
Median 3Y
14.3
Median 5Y
11.7
Industry
5.1
More Details
62.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
62.4
vs History
1
vs Industry
4
Median 3Y
31.1
Median 5Y
27.4
Industry
13.6
Forward
48.4
More Details
71.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
71.6
vs History
1
vs Industry
5
Median 3Y
37.1
Median 5Y
32.8
Industry
17
Forward
54.5
More Details
175.3
EV/OCF
EV/OCF
Enterprise Value to OCF
175.3
vs History
3
vs Industry
2
Median 3Y
42.3
Median 5Y
33.6
Industry
15.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
4
Median 3Y
50.1
Median 5Y
45.3
Industry
17.6
More Details
12.7
EV/IC
EV/IC
Enterprise Value to IC
12.7
vs History
3
vs Industry
9
Median 3Y
7.3
Median 5Y
5.6
Industry
1.9
More Details

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
724.1B USD 21.2 138.2 62.4 71.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.9 46.8 34.2 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
359.6B USD 4.4 8.9 11.8 15.6
US
Merck & Co Inc
NYSE:MRK
326.6B USD 5.3 141.6 33.7 53.4
UK
AstraZeneca PLC
LSE:AZN
188.4B GBP 5.1 39.5 140.7 225.8
CH
Novartis AG
SIX:NOVN
181.6B CHF 4.2 13.3 9.8 16.1
CH
Roche Holding AG
SIX:ROG
170.6B CHF 2.9 14.8 8.5 10.1
US
Pfizer Inc
NYSE:PFE
155.3B USD 2.7 73.3 11 16.3
FR
Sanofi SA
PAR:SAN
115B EUR 2.5 21.3 8.1 11.8
P/E Multiple
Earnings Growth
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 55.3
138.2
346%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
46.8
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
8.9
-20%
US
Merck & Co Inc
NYSE:MRK
141.6
7 454%
UK
AstraZeneca PLC
LSE:AZN
39.5
168%
CH
Novartis AG
SIX:NOVN
13.3
15%
CH
Roche Holding AG
SIX:ROG
14.8
26%
US
Pfizer Inc
NYSE:PFE
73.3
680%
FR
Sanofi SA
PAR:SAN
21.3
120%

See Also

Summary
LLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
LLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LLY stock valuation using valuation multiples.
Wall Street Estimates
LLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.